The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche/Genentech
SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bridge Medicines; Daiichi Sankyo/UCB Japan; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Jazz Pharmaceuticals; Kowa; Merck; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; Menarini; Pfizer; PrIME Oncology; Roche; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca; BMS; Hansoh; Hengrui Therapeutics; Hutchison MediPharma; Roche
 
Ross A. Soo
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Merck Serono; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech; Takeda; Yuhan
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Takeda; Yuhan
Research Funding - AstraZeneca; Boehringer Ingelheim
 
Min Hee Hong
Stock and Other Ownership Interests - GI biome; GI cell
Honoraria - AstraZeneca; AstraZeneca; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Merck; Roche; Yuhan
Research Funding - Yuhan
 
Jong-Seok Lee
No Relationships to Disclose
 
Maciej Bryl
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche/Genentech
 
Daphne W Dumoulin
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Achim Rittmeyer
No Relationships to Disclose
 
Chao-Hua Chiu
Honoraria - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma Europe; Janssen; Lilly; Merck KGaA; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Lilly; Merck KGaA; MSD; Novartis; Roche
Speakers' Bureau - Amgen; Lilly; MSD
 
Ozgur Ozyilkan
No Relationships to Disclose
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb Foundation; Pfizer
Speakers' Bureau - AstraZeneca Spain; Roche
Expert Testimony - MedSIR; Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Silvia Novello
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
 
Yuichi Ozawa
Honoraria - AstraZeneca; Chugai Pharma; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
 
Raymond Meng
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Patents, Royalties, Other Intellectual Property - Genentech
 
Tien Hoang
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Patents, Royalties, Other Intellectual Property - Genentech
 
Anthony Lee
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Xiaohui Wen
Employment - Roche
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Roche
 
Meilin Huang
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis